FindTrial
Sign In

Analysis of factors associated with blood pressure reduction and serum potassium elevation in hypertensive patients treated with esaxerenone (CS-3150) -Integrated analysis from CS-3150 phase 3 studies-

Analysis of factors associated with blood pressure reduction and serum potassium elevation in hypertensive patients treated with esaxerenone (CS-3150) -Integrated analysis from CS-3150 phase 3 studies- - Analysis of factors associated with blood pressure reduction and serum potassium elevation in hypertensive patients treated with esaxerenone (CS-3150)

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000047026
Enrollment
1470
Registered
2022-03-01
Start date
2022-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

None listed

Sponsors

Daiichi Sankyo Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who were assigned to the CS-3150 group in phase 3 studies (7 studies in total)

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

MeasureTime frame
Efficacy endpoint; Change in office sitting BP (systolic BP and diastolic BP) from baseline to Week 12 Safety endpoint; Number of patients with following serum potassium levels (1) 5.5 mEq/L and more (2) 6.0 mEq/L and more, or 5.5 mEq/L and more on two consecutive occasions—

Countries

Japan

Contacts

Public ContactKotaro Sugimoto

Daiichi Sankyo Co., Ltd. Primary Medical Science Department

sugimoto.kotaro.t7@daiichisankyo.co.jp03-6225-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026